|
| 仙灵骨葆胶囊治疗骨质疏松症的网络药理学分析 |
| Analysis of Pharmacological Mechanism of Xianling Gubao Capsule in Treating Osteoporosis Based on Network Pharmacology |
| 投稿时间：2019-03-20 修订日期：2019-05-22 |
| DOI： |
| 中文关键词: 仙灵骨葆 骨质疏松症 网络药理学,通路 |
| 英文关键词: |
| 基金项目:1.广东省中医药局项目(20164008)2.广东省中医院治未病专项(YN2016ZWB07)3.广东省中医院中医药科技学术研究专项(YN2015QN08) |
|
| 摘要点击次数: 322 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：运用网络药理学分析方法进行仙灵骨葆治疗OP的药理机制分析。方法：借助中药系统药理学数据库和分析平台(TCMSP)以及中药综合数据库(TCMID)获取仙灵骨葆活性成分以及相关靶标,运用Cytoscape3.7.1软件绘制“活性成分-靶标”网络图,以“osteoporosis”为关键词从GeneCards:SThe Human Gene Database获取OP相关基因,运用STRING数据分析平台进行PPI网络分析,运用DAVID数据分析平台进行GO生物过程富集以及KEGG通路富集分析,并运用Cytoscape3.7.1软件绘制“通路-靶标”网络图。结果：仙灵骨葆核心活性成分有槲皮素、山奈酚、木犀草素、淫羊藿苷元、丹参酮IIA等。核心靶标有PTGS2、PTGS1、ESR1等。PPI网络显示核心蛋白主要与调节细胞周期有关。GO生物过程亦与细胞周期有关,正调控NF-kappaB转录活性因子的过程是OP发生的机制之一,与现有研究符合,KEGG通路富集提示仙灵骨葆治疗OP作用集中于PI3K-Akt、TNF、MAPK、Estrogen等信号通路。结论：仙灵骨葆干预OP是通过多种途径、多种靶标、多种信号通路同时进行的,运用网络药理学方法可以在一定程度上对其进行预测。 |
| 英文摘要: |
| Object:To analyze the pharmacological mechanism of the treatment of osteoporosis (OP) with Xianling Gubao Capsule (XGC) based on network pharmacology. Methods: The active components and related targets of XGC were obtained by means of the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and the Traditional Chinese Medicine Integrated Database (TCMID), and Cytoscape (ver.3.7.1) was adopted for constructing the active component-target network. Considering OP as the Keyword, OP-related genes were obtained from Gene Cards: The Human Gene Database. Thereafter, GO bioprocess enrichment and KEGG pathway enrichment analysis were performed using DAVID data analysis platform. STRING data analysis platform and Cytoscape were respectively applied for PPI network analysis and the construction of passage-target network. Results: The core active components of XGC contain quercetin, kaempferol, luteolin, icariin, tanshinone IIA, etc. The core targets consist of PTGS2, PTGS1, ESR1, etc. The PPI network analysis shows that the core protein is primarily involved in regulating the cell cycle, with which the GO biological process is also associated. The process of positively regulating NF-κB transcriptional activator is one of the mechanisms of OP. Moreover, the KEGG pathway enrichment suggests that the effects of XGC on OP focus on PI3K-Akt, TNF, MAPK, Estrogen and other signaling pathways. Conclusion: The intervention of XGC in the treatment of OP is carried out simultaneously through multiple pathways, targets and signaling pathways, which can be predicted to some extent through network pharmacology. |
| 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|